(Total Views: 397)
Posted On: 09/07/2019 3:51:05 AM
Post# of 155191
Maybe. Though, maybe slowing down leronlimab’s approval looks good on a resume for BP. Just crazy.
Oh by the way, here is Maraviroc in MDR2, looks like at 24 weeks, VL<50 was around 45%. So leronlimab 325mg is better than maraviroc’s best, almost by double, same with IZ. Yet we still need better.
Also 17 patients died during this study. Did they really need a placebo group? Seems unethical.
https://www.nejm.org/doi/full/10.1056/nejmoa0803152
Oh by the way, here is Maraviroc in MDR2, looks like at 24 weeks, VL<50 was around 45%. So leronlimab 325mg is better than maraviroc’s best, almost by double, same with IZ. Yet we still need better.
Also 17 patients died during this study. Did they really need a placebo group? Seems unethical.
https://www.nejm.org/doi/full/10.1056/nejmoa0803152
(0)
(0)
